MYELODYSPLASTIC SYNDROME (MDS)
Clinical trials for MYELODYSPLASTIC SYNDROME (MDS) explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROME (MDS) trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROME (MDS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Immune-Boosting drug targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study tests a new drug called CLN-049 in about 60 adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or not responded to treatment. CLN-049 is designed to help the body's immune cells attack cancer cells. The main goals are …
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated May 17, 2026 03:14 UTC
-
Experimental combo aims to tame tough cancers
Disease control Recruiting nowThis early-stage study tests two drugs—alpelisib and pembrolizumab—together in people with metastatic breast cancer or melanoma that has spread. The main goal is to find a safe dose and watch for side effects. About 50 adults whose cancer has worsened after standard treatments wi…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:13 UTC
-
New combo therapy targets leukemia stem cells in MDS and AML
Disease control Recruiting nowThis early-phase trial tests a new drug called nadunolimab combined with standard treatments (azacitidine, with or without venetoclax) in 40 adults with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal is to find a safe dose and see if the combin…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:09 UTC
-
New hope for fanconi anemia: gentler transplant may cut risks
Disease control Recruiting nowThis study tests a stem cell transplant using lower doses of chemotherapy drugs (busulfan, cyclophosphamide, fludarabine) for people with Fanconi Anemia who don't have a perfectly matched donor. The goal is to reduce serious side effects while still helping the body accept the ne…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated May 12, 2026 13:48 UTC
-
New cord blood transplant could help bone marrow disease patients
Disease control Recruiting nowThis study tests a new way to do stem cell transplants for people with severe aplastic anemia or a related bone marrow disease called MDS. It combines stem cells from a family member with specially grown cord blood cells from an unrelated donor to help the new cells grow faster a…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated May 11, 2026 20:54 UTC
-
Could a pill replace shots for this bone marrow disease?
Disease control Recruiting nowThis early-phase study tests an oral combination of two drugs (ASTX030) for people with myelodysplastic syndrome (MDS), a bone marrow disorder. The goal is to find a dose that works as well as the standard injected treatment but in a more convenient pill form. About 40 adults wit…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE1 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
New study asks: What's it like living with Low-Risk MDS?
Knowledge-focused Recruiting nowThis study aims to understand the quality of life, symptoms, and unmet needs of 50 people in Japan with low-risk myelodysplastic syndrome (MDS) or unexplained anemia. Participants will fill out questionnaires and some will have interviews about their experiences. No new treatment…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated May 15, 2026 11:58 UTC
-
New study aims to personalize chemo dosing for blood cancer patients
Knowledge-focused Recruiting nowThis study looks at how kidney function and race/ethnicity affect the way the drug treosulfan works in people with acute myeloid leukemia or myelodysplastic syndrome who are getting a stem cell transplant. The goal is to find the safest dose for those with kidney problems. About …
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE1 • Sponsor: medac GmbH • Aim: Knowledge-focused
Last updated May 11, 2026 20:49 UTC